Article Information
vol. 42 no. 3 785-801
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 21, 2012
- Accepted January 23, 2013
- Published online September 2, 2013.
Article Versions
- previous version (February 8, 2013 - 06:41).
- You are viewing the most recent version of this article.
Copyright & Usage
©ERS 2013
Author Information
- Roland Diel1,
- Robert Loddenkemper2,
- Jean-Pierre Zellweger3,
- Giovanni Sotgiu4,
- Lia D'Ambrosio5,
- Rosella Centis5,
- Marieke J. van der Werf6,
- Masoud Dara7,
- Anne Detjen8,
- Peter Gondrie9,
- Lee Reichman10,
- Francesco Blasi11 and
- Giovanni Battista Migliori5⇑
- on behalf of the European Forum for TB Innovation
- 1Institute for Epidemiology, University Medical Hospital Schleswig-Holstein, Member of the German Center for Lung Research (DZL), Kiel
- 2German Central Committee Against Tuberculosis, Berlin, Germany
- 3Swiss Lung Association, Bern, Switzerland
- 4Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Sassari
- 5World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate
- 11Dipartimento Fisiopatologia Medico-Chirurgica e dei Trapianti, University of Milan, IRCCS Fondazione Cà Granda, Milan, Italy
- 6European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- 7World Health Organization, Regional Office for Europe, Copenhagen, Denmark
- 8International Union Against Tuberculosis and Lung Disease, New York, NY,
- 10Global Tuberculosis Institute, New Jersey Medical School, Newark, NJ, USA
- 9International Unit, KNCV Tuberculosis Foundation, The Hague, The Netherlands
- G.B. Migliori, World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Via Roncaccio 16, 21049, Tradate, Italy. E-mail: giovannibattista.migliori{at}fsm.it
Article usage
Altmetrics
Vol 42 Issue 3
Table of Contents
Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination
Jump To
- Article
- Abstract
- Abstract
- Introduction
- From Zorini to Thibela trial and between: the TB preventive treatment approach
- TB latency, testing and preventive treatment: what do we know and not know so far?
- When and how to screen for LTBI?
- Indications for preventive treatment
- Cost-effectiveness of preventive programmes for LTBI
- LTBI in contacts of patients with MDR-TB
- Accelerating towards zero infections, zero cases, zero deaths: playing the preventive treatment card
- Conclusions
- Acknowledgments
- Footnotes
- References
- Figures & Data
- Info & Metrics